Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | January 12, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date January 12, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.98 · Expires 2036-01-12 | Direct | 54,876 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 54,876 · Balance 54,876 F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Mar 3, 2026 18:47 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 54,876 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001140361-26-007642 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,876 Underlying: Common Stock · 54,876 shares Expires 2036-01-12 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 11, 2025 Filed Jun 11, 2025 18:00 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 22,700 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001140361-25-022226 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2035-06-11 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 24, 2024 Filed Jun 25, 2024 16:05 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001140361-24-031291 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-24 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| July 14, 2023 Filed Jul 17, 2023 17:25 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantEmployee Stock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $5.13 | $0.00 |
DisclosureSEC source: 0001140361-23-034829 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2033-07-14 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 28, 2022 Filed Jun 29, 2022 16:15 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $3.90 | $0.00 |
DisclosureSEC source: 0001140361-22-024469 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2032-06-28 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on the first anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer as a director through such date. Read SEC document |
| June 17, 2021 Filed Jun 17, 2021 18:58 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001140361-21-021493 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: The Stock Option will vest in full and become fully exercisable on June 17, 2022. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 18:32 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 1,874 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001140361-20-014764 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,874 Underlying: Common Stock · 1,874 shares Expires 2030-06-23 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 23, 2023. Read SEC document |
| April 08, 2020 Filed Apr 9, 2020 16:49 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001140361-20-008509 · form4.xml · derivative · entry 1 Iliev Ilian · CIK 0001808804 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2030-04-08 F1 · derivative.exercise_date: One-third (1/3) of the shares underlying the option shall vest upon each of the first, second and third anniversaries of the date of grant, such that the option will be fully vested on April 8, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.